Cronos Introduces Premium Brand to Israeli Medical Cannabis Market

TORONTO – Cronos Group Inc. has launched its premium Cannabis brand in Israel, making five indoor-grown flower strains available to medical patients through pharmacies across the country.

The announcement represents the latest step in Cronos’ strategy to extend its branded products beyond North America into established international markets. Israel maintains one of the world’s more mature and regulated medical Cannabis systems, with strict quality standards and a patient base that values consistent, high-end offerings.

The initial rollout focuses on core flower products from Lord Jones®, a brand known in the U.S. and Canada for its emphasis on craftsmanship and refined presentation. Additionally, Cronos revealed plans to release special-edition and limited-run items in Israel over time. The company already operates in the country through its long-standing joint venture, Cronos Israel, which produces and distributes the Peace Naturals™ medical brand – a line that has held a leading position in local sales volumes and revenue in recent quarters.

Mike Gorenstein, Cronos’ chairman, president and CEO, described Israel as a longstanding priority in the company’s approach to global product distribution. Adam Wagner, general manager of Cronos Israel, highlighted the launch as a way to deliver a premium tier suited to the market’s expectations for expertise and quality control.

This move arrives as Cronos continues to report solid performance in Israel, where medical Cannabis demand has supported record results for its existing operations. The company has pursued measured international growth, including exports and partnerships in Europe, while maintaining a focus on differentiated brands rather than broad commodity supply.

For the broader Cannabis sector, expansions like this one illustrate how multinational operators are leveraging established medical frameworks abroad to build brand equity and revenue streams outside their home markets. Israel’s market, though medical-only and tightly regulated, offers a stable testing ground for premium positioning.

As Cronos pins flags on the world map, succeeding in Israel will require sustained patient uptake of the Lord Jones® line, as well as the company’s ability to navigate local competitive dynamics. Meanwhile, this development adds another layer to Cronos’ portfolio amid ongoing discussions about regulatory shifts in larger markets like the United States.